What is the best treatment for acute coronary syndrome?
Medications
- Thrombolytics (clot busters) help dissolve a blood clot that’s blocking an artery.
- Nitroglycerin improves blood flow by temporarily widening blood vessels.
- Antiplatelet drugs help prevent blood clots from forming and include aspirin, clopidogrel (Plavix), prasugrel (Effient) and others.
What are the antithrombotic meds?
Antithrombotic drugs in routine use include antiplatelet drugs (aspirin, clopidogrel, and glycoprotein IIb/IIIa receptor antagonists) and anticoagulants (unfractionated and low molecular weight heparin, warfarin, and direct thrombin inhibitors).
What is the initial drug therapy for acute coronary syndrome?
Morphine (or fentanyl) for pain control, oxygen, sublingual or intravenous (IV) nitroglycerin, soluble aspirin 162-325 mg, and clopidogrel with a 300- to 600-mg loading dose are given as initial treatment.
Why are anticoagulants used for acute coronary syndrome?
Anticoagulation in conjunction with antiplatelet therapy is central to the management of acute coronary syndromes (ACS). When used effectively it is associated with a reduction in recurrent ischaemic events including myocardial infarction and stent thrombosis as well as a reduction in death.
Why is aspirin given for acute coronary syndrome?
Aspirin is effective in reducing the blood clots that are blocking a coronary artery during an acute heart attack. Anyone who has already had a heart attack, or who has an increased risk of having one in the future, should always carry a few non-coated adult aspirins with them.
Which of the following is a thrombolytic agent?
The FDA approved the following thrombolytic agents for use in acute PE: alteplase, urokinase, and streptokinase.
Why is heparin given in acute coronary syndrome?
found that short-term treatment of acute coronary syndromes with unfractionated heparin or low-molecular-weight heparin (LMWH) in addition to aspirin results in about a 50% reduction in the risk of myocardial infarction or death.
Why is fondaparinux given in Nstemi?
Importance Fondaparinux was associated with reduced major bleeding events and improved survival compared with low-molecular-weight heparin (LMWH) in a large randomized clinical trial involving patients with non–ST-segment elevation myocardial infarction (NSTEMI).
Do you give clopidogrel in STEMI?
Oral clopidogrel (Plavix) at a dosage of 75 mg daily should be added to aspirin therapy in patients with STEMI, whether or not they undergo reperfusion therapy.
Why is it important that clopidogrel and aspirin are given as soon as an acute myocardial event has happened?
Aspirin combined with clopidogrel can effectively reduce the occurrence of re-thrombosis after PCI and improve the recovery of cardiac function after acute operation, moreover the safety is high. It has important clinical application values.
What are 5 thrombolytic drugs?
The most commonly used clot-busting drugs — also known as thrombolytic agents — include:
- Eminase (anistreplase)
- Retavase (reteplase)
- Streptase (streptokinase, kabikinase)
- t-PA (class of drugs that includes Activase)
- TNKase (tenecteplase)
- Abbokinase, Kinlytic (rokinase)
What is thrombolytic therapy used for?
Thrombolytic therapy is the use of drugs to break up or dissolve blood clots, which are the main cause of both heart attacks and stroke.
Is warfarin an anticoagulant or antithrombotic?
Warfarin is the oral anticoagulant most frequently used to control and prevent thromboembolic disorders. Prescribing the dose that both avoids hemorrhagic complications and achieves sufficient suppression of thrombosis requires a thorough understanding of the drug’s unique pharmacology.
What is aspirin antithrombotic?
Antithrombotic effects of aspirin (acetylsalicylic acid) reported in the literature. The major well-documented antithrombotic action of aspirin is to acetylate cyclooxygenase-1 (COX-1) in platelets, leading to the inhibition of thromboxane A2 (TXA2) synthesis.
Is heparin contraindicated acute coronary syndrome?
Heparin, either unfractionated or as the low-molecular-weight version, should be administered early in patients with AMI or the more severe forms of non-AMI acute coronary syndrome (ACS); patients with lower risk ACS presentations may not benefit from such therapy.